BioAge's BGE-102 Delivers Rapid and Significant Inflammation Reduction in Phase 1 Data—Promising Step Toward Cardiovascular Risk Therapy

BGE-102 Achieves 86% hsCRP Reduction and Normalizes Inflammatory Risk Markers in Phase 1 Study

BioAge Labs (NASDAQ:BIOA) has reported new interim Phase 1 results for BGE-102, their brain-penetrant NLRP3 inhibitor, shining a spotlight on a promising candidate for cardiovascular disease risk management. In a multiple ascending dose (MAD) cohort, obese participants with elevated high-sensitivity C-reactive protein (hsCRP) saw median hsCRP levels fall by 86% after two weeks of 120 mg daily BGE-102 dosing. Remarkably, 93% of these participants reached hsCRP levels below 2 mg/L, a threshold associated with substantially reduced cardiovascular risk.

Clinical Signals Point to Best-in-Class Potential for BGE-102

The strength and speed of BGE-102’s impact on key inflammation markers provide compelling clinical evidence. Not only did nearly all participants meet the desired hsCRP threshold within two weeks, but many demonstrated this effect by Day 7, highlighting the rapid onset of action. These reductions extend to other key markers, including interleukin-6 (IL-6), a relevant factor upstream of hsCRP production, and fibrinogen, an independent predictor of cardiovascular risk. The across-the-board declines amplify the drug’s profile as a comprehensive anti-inflammatory agent potentially suited for broad use in primary care.

Well-Tolerated Safety Profile Strengthens Prospects

BGE-102 continued to show a favorable safety and tolerability profile in Phase 1. Reported adverse events were infrequent and mild to moderate in severity, with no dose-dependent pattern or dose-limiting toxicities observed. These findings align with prior interim data where BGE-102 was well tolerated in both single and multiple ascending dose cohorts and exhibited reliable, dose-proportional pharmacokinetics.

Clinical Milestones Set for 2026 as BGE-102 Eyes Phase 2

The company plans to complete its full Phase 1 trial and report additional data on lower dose cohorts during the first half of 2026. A Phase 2a proof-of-concept trial is scheduled to begin in the same period, enrolling approximately 100 patients with obesity and cardiovascular risk factors to evaluate BGE-102's sustained effect over 12 weeks, with a primary endpoint of percent change in hsCRP. This forward momentum underscores the potential impact BGE-102 could have for a growing patient population seeking inflammation control as a complement or alternative to existing therapies.

Key Takeaways: A New Oral Anti-Inflammatory Candidate with Potential for Wide Impact

BGE-102’s rapid, robust reduction in validated markers of cardiovascular and systemic inflammation is notable, positioning it as a leading oral therapy prospect. For physicians and patients, these data suggest a new horizon in managing cardiovascular risk beyond cholesterol, especially for those who prefer an oral regimen over injectables. Investors and clinicians alike will be watching for the Phase 2a trial’s outcome, which could shape the evolving landscape of inflammation-driven disease treatment options. Will BGE-102's performance in larger studies confirm these early promising signs? That’s the question to monitor as development continues into 2026.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI